ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis

Hee Kyung Ahn; Boram Han; Su Jin Lee; Taekyu Lim; Jong Mu Sun; Jin Seok Ahn; Myung Ju Ahn; Keunchil Park

doi:10.1016/j.lungcan.2012.02.003

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis

Hee Kyung Ahn, Boram Han, Su Jin Lee, Taekyu Lim, Jong Mu Sun, Jin Seok Ahn, Myung Ju Ahn, Keunchil Park

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.

Original language	English
Pages (from-to)	253-254
Number of pages	2
Journal	Lung Cancer
Volume	76
Issue number	2
DOIs	https://doi.org/10.1016/j.lungcan.2012.02.003
State	Published - May 2012

Bibliographical note

Funding Information:
Crizotinib was supported by Pfizer . The authors thank Drs. Keith Wilner and Sang-Yoon Lee and clinical research associates of Pfizer Korea.

Keywords

ALK inhibitor
ALK positive NSCLC
Leptomeningeal carcinomatosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2012.02.003

Cite this

@article{4457ffca62134e86bbf2bc3d3a9d2823,

title = "ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis",

abstract = "Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.",

keywords = "ALK inhibitor, ALK positive NSCLC, Leptomeningeal carcinomatosis",

author = "Ahn, {Hee Kyung} and Boram Han and Lee, {Su Jin} and Taekyu Lim and Sun, {Jong Mu} and Ahn, {Jin Seok} and Ahn, {Myung Ju} and Keunchil Park",

note = "Funding Information: Crizotinib was supported by Pfizer . The authors thank Drs. Keith Wilner and Sang-Yoon Lee and clinical research associates of Pfizer Korea.",

year = "2012",

month = may,

doi = "10.1016/j.lungcan.2012.02.003",

language = "English",

volume = "76",

pages = "253--254",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis

AU - Ahn, Hee Kyung

AU - Han, Boram

AU - Lee, Su Jin

AU - Lim, Taekyu

AU - Sun, Jong Mu

AU - Ahn, Jin Seok

AU - Ahn, Myung Ju

AU - Park, Keunchil

N1 - Funding Information: Crizotinib was supported by Pfizer . The authors thank Drs. Keith Wilner and Sang-Yoon Lee and clinical research associates of Pfizer Korea.

PY - 2012/5

Y1 - 2012/5

N2 - Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.

AB - Anaplastic lymphoma kinase (ALK) inhibitor has shown dramatic efficacy in non-small cell lung cancer (NSCLC) patients harboring ALK rearrangements in phase I trial. Herein we report two cases of NSCLC patients with leptomeningeal carcinomatosis (LM), treated with ALK inhibitor under emergent use of investigational new drug combined with intrathecal methotrexate treatment. Progression free survival was 10 months and 6 months, respectively, and little additional toxicities were observed. These results suggest that ALK inhibitor might be safely administered even in patients or those with metastases in central nervous system.

KW - ALK inhibitor

KW - ALK positive NSCLC

KW - Leptomeningeal carcinomatosis

UR - http://www.scopus.com/inward/record.url?scp=84862789835&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2012.02.003

DO - 10.1016/j.lungcan.2012.02.003

M3 - Article

C2 - 22385925

AN - SCOPUS:84862789835

SN - 0169-5002

VL - 76

SP - 253

EP - 254

JO - Lung Cancer

JF - Lung Cancer

IS - 2

ER -

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this